Senior CDER Management Panel Could Facilitate Novel Therapy Approval
This article was originally published in The Pink Sheet Daily
CDER Director Janet Woodcock is creating an executive-level forum to deliberate medical policies, including those needed to smooth drug reviews. She envisions stakeholder input on topics for discussion by the panel.
You may also be interested in...
US FDA Accelerated Approval Council Required Under Senate User Fee Bill
Intra-agency group would be tasked with ensuring consistent use of the expedited pathway across the FDA, with duties potentially including development of best practices, product review team training, and advising on withdrawals, according to the Senate's bipartisan user fee legislation.
FDA’s Breakthrough Products: Could Patients Drive The Designations?
Sen. Bennet is receiving letters from patients asking to talk with FDA about products they think could be a breakthrough.
CDER Policy Council Urged To Address Manufacturer/Payer Communications
PhRMA and the Medical Information Working Group say the lack of clarity around FDAMA Sec. 114’s provisions governing dissemination of health care economic data to formulary committees warrants the medical policy council’s attention.